Rituximab for membranous nephropathy and immune disease: Less might be enough

Nature Clinical Practice Nephrology

Volumn 5, Issue 2, 2009, Pages 76-77

  Ruggenenti, Piero ^a,b   Cravedi, Paolo ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD20 ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN G; RITUXIMAB;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CRYOGLOBULINEMIA; DRUG DOSE TITRATION; DRUG MECHANISM; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; HOSPITALIZATION COST; HUMAN; KIDNEY FUNCTION; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; PURE RED CELL ANEMIA; REPEATED DRUG DOSE; SHORT SURVEY; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOLOGIC FACTORS;

EID: 59049089769     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph1007     Document Type: Short Survey

References (11)

1. Remuzzi G et al. (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924
2. Ruggenenti P et al. (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14: 1851-1857
3. Fervenza FC et al. (2008) Rituximab treatment for idiopathic membranous nephropathy. Kidney Int 73: 117-125
4. Perna A et al. (2004) Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 44: 385-401
5. Salama AD and Pusey CD (2006) Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2: 221-230
6. Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589
7. Cravedi P et al. (2007) Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2: 932-937
8. Arnold DM et al. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146: 25-33
9. Albert D et al. (2008) Variability in the biological response to anti-CD20 B-cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67: 1724-1731
10. US Food and Drug Administration (online 18 December 2006) 2006 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements [http://www.fda. gov/medwatch/safety/2006/safety06.htm#rituxan] (accessed 21 October 2008)
11. Fairweather H et al. (2008) Abbreviated dose rituximab for immune-mediated hematological disorders. Am J Hematol 83: 554-557